Design project of the Federal hi-tech medical radiology center in Dimitrovgrad

Properties

  • Address:

    5 В, Kurchatov avenue, Dimitrovgrad

  • Customer:

    Federal Medical-Biological Agency

  • Built-up area:

    35688.79 sq. m

  • Destination:

    Design

  • Start date:

    April, 2009

  • Date of completion:

    December 3, 2010

About

The Federal hi-tech medical radiology center is a prevention and treatment facility, complex of structural subdivisions of which provides hi-tech therapeutic and diagnostic aid to FMBA of Russia contingent and population using modern acievements of the world medical science and practice.


 

There are laid out for construction more than 30 hectares, on which is located a complex of buildings with a total area of ​​99,000 m². 

The staff of the Center being built will be more than 1400 people, including 340 doctors and 460 medical staff. 

 
 
 

Unlike other centers that use only separate nuclear medicine technologies, Dimitrovgrad will have the first unique closed-loop complex in the area, where all the methods of diagnostics and treatment used in nuclear medicine are presented on one site.

FICMR FMBA of Russia will be the largest in Europe among specialized medical institutions.

   
   
   

 Composition of the center

  • Consultative polyclinic for 240 visits per shift;

  • Center for Positron Emission Tomography (PET Center);

  • The building of radionuclide therapy for 37 active beds;

  • Radiological pavilion;

  • The building of proton therapy for up to 1200 patients per year;

  • Rehabilitation pavilion;

  • 24-hour hospital with 312 beds;

  • Supporting departments.

   
   
   

Radionuclide diagnosis 

  • Ability to diagnose functional abnormalities of organs in the early stages of the disease, before the clinical manifestation of the symptoms of the disease;

  • Obtaining structural-functional images of human organs;

  • Obtaining a qualitative-quantitative assessment of organ vital activity or development of pathological processes;

  • Surveys can be conducted in the clinic and ambulatory conditions;

  • Surveys can repeat without risk to the patient;

  • The method is non-invasive and has practically no contraindications, side effects, age limitations;

  • Duration of the examination is from 30 to 90 minutes;

  • One-time radiation load is about 10 times less in comparison with the X-ray examination.

   
   
   

Positron Emission Tomography (PET)

  • The sensitivity is 2 orders of magnitude higher in comparison with SPECT.

  • Ability to measure functional changes in biochemical processes in the patient's body:

    • High accuracy of benign from malignant;
    • Timely determination of the effectiveness of the applied treatment strategy;
    • Early diagnosis - half the success in fighting cancer;
  • The possibility of determining metastases 1-2 mm in size;

  • Control of the entire body of the patient for the presence of a primary tumor and metastasis in one session.

   
   
   

Radionuclide Therapy

Treatment with minimal side effects:

  •  Selectivity of damage to the tumor or pathological focus;

  •  Simultaneous impact on all pathological focuses;

  •  Minimal damage to healthy tissue;

  •  Good tolerability of therapy;

  •  Relatively short hospitalization time.

   
   
   

Remote gamma-therapy 

The large penetrating power of this type of radiation makes it possible to widely use remote gamma-therapy for irradiation of deep-lying neoplasms.

   
   
   

Proton beam therapy 

Proton therapy is by far the most modern and effective method for treating the vast majority of inoperable and immunoreficient tumors:

  • Possibility of high doses irradiated to the target, without causing any noticeable harm to the healthy tissues adjacent to it;

  • Reduction of the risk of recurrence of the disease by 50%;

  • Possibility of irradiating small and super-small targets;

  • Reduced risk of complications;

  • Reduced integral dose received by the patient for the procedure;

  • High probability of complete destruction of tumor cells.

Documentation